nect Biopharma (US:CNTB)2025-11-12 14:02Financial Performance - License and collaboration revenues for Q3 2025 were $16,000, a decrease of 98.7% compared to $1.2 million in Q3 2024[10] - Net loss for Q3 2025 was $17.2 million, or $0.31 per share, compared to a net loss of $12.9 million, or $0.23 per share, in Q3 2024[14] - Total operating expenses for Q3 2025 were $17.7 million, compared to $15.1 million in Q3 2024, reflecting a 17.4% increase[20] Expenses - Research and development expenses for Q3 2025 were $11.1 million, up 23.3% from $9.0 million in Q3 2024[14] - General and administrative expenses for Q3 2025 were $6.6 million, an increase of 8.7% compared to $6.1 million in Q3 2024[14] Assets and Equity - Total assets as of September 30, 2025, were $67.4 million, down from $101.3 million as of December 31, 2024[22] - Total shareholders' equity decreased to $55.4 million as of September 30, 2025, from $92.2 million at the end of 2024[22] Future Outlook - Cash, cash equivalents, and short-term investments were $54.8 million as of September 30, 2025, expected to fund operations into 2027[10] - The company expects to report topline data from ongoing Phase 2 Seabreeze STAT studies in the first half of 2026[5] - Simcere submitted a New Drug Application for rademikibart for atopic dermatitis, with potential milestone payments of up to $110 million[10]